BiotechTube
Kinea Bio

Kinea Bio

Cambridge, United States· Est.
kineabio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $12M

Overview

Kinea Bio is a private, pre-clinical-stage biotech developing innovative gene therapy platforms and programs for neuromuscular diseases (NMDs) with high unmet need. The company has built a multi-faceted technology suite, including SIMPLI-GT™ for large gene delivery, MyoXpress™ for tuned muscle expression, myotropic capsids for targeted delivery, and BioDrone™ for non-immunogenic repeat administration. Backed by respected scientific founders, non-dilutive NIH grants, and foundation investments, Kinea is advancing a pipeline led by programs for Duchenne Muscular Dystrophy (DMD) and dysferlinopathy.

Neuromuscular Diseases

Technology Platform

Multi-platform approach: SIMPLI-GT™ for large gene delivery via split inteins, MyoXpress™ for tunable muscle-specific expression, engineered Myotropic Capsids for targeted AAV delivery, and BioDrone™ non-viral nanovesicles for repeat dosing.

Funding History

1
Total raised:$12M
Seed$12M

Opportunities

Kinea's platforms address fundamental limitations in gene therapy, creating opportunities to develop best-in-class treatments for large-market diseases like DMD and high-value orphan diseases like dysferlinopathy.
Success in its lead programs could validate its platforms for broader application across dozens of other neuromuscular and monogenic disorders involving large genes.

Risk Factors

High technical risk associated with novel platform mechanisms like in vivo protein splicing and non-viral repeat dosing.
Intense competition in core indications like DMD from companies with greater resources.
Dependence on future large capital raises to advance from pre-clinical to clinical stages.

Competitive Landscape

Kinea operates in the competitive neuromuscular gene therapy arena, facing large biopharma (e.g., Sarepta, Pfizer) and biotech rivals with micro-dystrophin and gene editing approaches for DMD. Its differentiation hinges on demonstrating superior efficacy from larger dystrophin proteins and its multi-platform strategy for targeted, tunable, and repeatable delivery.

More companies in RNA Therapeutics (non-mRNA) →More companies in United States →